Committed to solid profitable growth Investor Introduction Q3 2025 Presentation Titel Forward looking and intended use statements Crucial to advancing science Improving healthcare for all Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, d ...

Core Insights - Qiagen N.V. is recognized as one of the most oversold healthcare stocks in 2025, focusing on expanding its precision medicine capabilities through innovative testing solutions [1] Financial Performance - In Q2 2025, Qiagen reported a 7% year-over-year growth in net sales, driven by strong adoption of key products like QIAstat-Dx and QuantiFERON [2] - The company plans to launch three new instruments in late 2025 to enhance diagnostic capabilities and support future growth [2] Product Innovations - Qiagen has advanced its precision oncology portfolio with new QIAseq panels that enable fast and comprehensive cancer genomic profiling, improving cost-effectiveness for laboratories [3] - Innovations also include QIAseqHYB Read Panels for long-read sequencing, addressing complex genomic regions and supporting various next-generation sequencing platforms [3] Strategic Developments - A significant milestone for Qiagen in 2025 is the FDA clearance and commercial rollout of QIAstat-Dx Rise, which is expected to enhance diagnostic access and testing capacity in the U.S. healthcare market [4] - These developments align with Qiagen's strategy to strengthen its molecular diagnostics offerings and expand its role in precision medicine and biotherapeutic development [4]

Core Insights - QIAGEN N.V. (QGEN) has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems, including an expanded Meningitis/Encephalitis (ME) Panel for diagnosing central nervous system (CNS) infections [1][9] - The expanded ME Panel offers coverage for 16 clinically relevant targets, including cytomegalovirus (CMV) and Streptococcus pyogenes, with a launch planned for September 2025 [4][5][9] - QIAGEN's market capitalization stands at $9.82 billion, with an earnings yield of 5%, significantly higher than the industry average of -22.8% [3] Company Developments - Following the certification announcement, QIAGEN's shares increased by 0.1% to $46.06, indicating positive market sentiment [2][9] - The QIAstat-Dx system can deliver results in about an hour, facilitating early and accurate treatment decisions for clinicians [6] - QIAGEN has installed over 4,600 QIAstat-Dx systems globally, highlighting its critical role in disease diagnosis [10] Industry Context - The global central nervous system therapeutics market is projected to reach $254.6 billion by 2030, growing at a CAGR of 7.7% from 2025 to 2030, driven by an aging population and increased awareness of mental health issues [12] - QIAGEN's advancements in molecular diagnostics align with the growing demand for high-quality diagnostic solutions in the healthcare sector [2][9]

Company Overview - Qiagen N.V. is a global leader in molecular diagnostics and sample preparation technologies, headquartered in the Netherlands and operating in over 30 countries under CEO Thierry Bernard [2] - The company offers a wide range of solutions including nucleic acid extraction systems, PCR reagents, digital PCR platforms, next-generation sequencing kits, and proteomics tools [2] Financial Performance - In Q2 2025, Qiagen reported net sales of $534 million, representing a 7% increase from the previous year [3] - The adjusted operating income margin was 29.9%, an increase of 1.5 percentage points [3] - Growth was driven by strong demand for products such as QIAstat-Dx, which grew 41% on a constant exchange rate (CER), and QuantiFERON, which increased 11% CER [3] - The company raised its full-year 2025 net sales growth outlook to 4–5% CER and reaffirmed its adjusted diluted EPS targets [3] Product Innovation - Qiagen launched QIAseq xHYB Long Read Panels to enhance target enrichment for long-read sequencing platforms, allowing for more detailed analysis of complex genomic regions [4] - The company is expanding its digital and automation offerings, with growth in QIAcuity digital PCR systems and the QIAGEN Digital Insights software platform [4] - Qiagen is preparing to launch three new instruments by late 2025 to strengthen its molecular diagnostics capabilities [4]

Core Insights - QIAGEN reported a strong performance in the first half of the year, achieving a 7% growth rate in Q1 and a 6% growth rate in Q2, which is approximately double the typical growth rate in the diversified tools sector [1] - The company has increased both its revenue and EPS guidance following the first quarter, indicating a positive outlook for profitability [1] - QIAGEN emphasizes the importance of its five pillars of growth and aims to be a top player in each of its market segments [1]

Company Performance - QIAGEN reported a 7% growth rate in Q1 and a 6% growth rate in Q2, which is approximately double the typical growth rate in the diversified tools sector [1] - The company has increased both its revenue guidance and EPS guidance after Q1, indicating strong profitability [1] Strategic Focus - QIAGEN emphasizes its commitment to being a top 1 to top 3 player in its key growth areas, referred to as the "5 pillars of growth" [1]

Summary of Qiagen (NYSE: QGEN) 2025 Conference Call Company Overview - **Company**: Qiagen (NYSE: QGEN) - **Date of Conference**: September 10, 2025 - **Key Speakers**: CFO Roland Sackers, IR John Gilardi Key Points Financial Performance - Qiagen reported a **7% growth rate in Q1** and a **6% growth rate in Q2** of 2025, indicating a positive start to the year [3][4] - The company has increased its revenue and EPS guidance following the first quarter [3][4] - The **five pillars of growth** are crucial for Qiagen's strategy, with a focus on being a top player in all segments [4] Product Performance - **QuantiFERON**: The largest product for Qiagen, has shown **20+ quarters of double-digit growth**. The market is still largely dominated by a 120-year-old skin test, presenting a significant penetration opportunity [4][24] - **QIAstat-Dx**: Strong growth in North America attributed to recent FDA approvals and expansion into syndromic testing [35][38] - **Sample Preparation**: Improvement noted, with new product launches expected, including QIAsymphony Connect, QIASprint Connect, and QIAmini [5][13][17] Market Dynamics - The **U.S. academic market** is facing challenges, with NIH funding contributing **4-5%** of total revenues. However, consumables business remains strong [7][8] - **China Market**: Currently experiencing a decline, with sales at **4-5%** of total revenues. Qiagen is adopting a two-pronged strategy to address structural issues in this market [10][11] - The **diagnostics market** in China is competitive, with **20-25 copycat competitors**. Qiagen is cautious about expecting a return to growth in this region [11] Growth Opportunities - The company is optimistic about the **sample prep market**, aiming for growth acceleration to **3-4%** over time, despite current challenges [22] - **QuantiFERON** has potential for growth due to increasing mandatory testing requirements in various sectors [24][26] - **Digital PCR (QIAcuity)**: Expanding into clinical applications, with significant opportunities in oncology and infectious diseases [41][43] Margin and Profitability - Qiagen is on track to achieve an adjusted operating margin of **31%** earlier than 2028, with expectations of **29-30%** by the end of the year [44][45] - The company is focusing on efficiency projects and better utilization of resources to enhance profitability [45] Capital Allocation - Qiagen has initiated a dividend and is active in share repurchases, with a recent approval for a **$500 million share buyback** [47][48] - The company maintains a balanced approach to capital allocation, investing in organic growth and potential acquisitions [47] Conclusion - Qiagen is navigating a complex market landscape with a focus on growth through innovation in product offerings and strategic market positioning. The company remains optimistic about its financial outlook and growth opportunities across various segments.

Group 1: AI Investment Opportunity - Artificial intelligence is considered the greatest investment opportunity of our lifetime, with a strong emphasis on the urgency to invest now [1] - Wall Street is investing hundreds of billions into AI, but there is a critical question regarding the energy supply needed to support this technology [2] - AI data centers consume as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2] Group 2: Company Overview - A specific company, largely overlooked by AI investors, is positioned to benefit from the increasing demand for energy due to AI [3] - This company owns critical energy infrastructure assets and is involved in the U.S. LNG exportation sector, which is expected to grow under the current administration's energy policies [7] - The company is debt-free and has a significant cash reserve, amounting to nearly one-third of its market cap, making it financially robust [8] Group 3: Market Position and Valuation - The company is trading at less than 7 times earnings, which is considered undervalued compared to its potential in the AI and energy sectors [10] - It has a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines without a premium [9] - Wall Street is beginning to take notice of this company as it benefits from various market trends without the high valuations typical of the sector [8] Group 4: Future Outlook - The future of energy is closely tied to AI, with a focus on the need for infrastructure to support this technological shift [6] - The influx of talent into the AI sector is expected to drive rapid advancements and innovative ideas, reinforcing the importance of investing in this field [12] - The company is well-positioned to capitalize on the upcoming AI energy boom, making it a compelling investment opportunity [14]

Core Insights - QIAGEN reported a strong start to the year with a 6% overall growth rate in the second quarter, indicating resilience despite market volatility [1] - The company's business model is heavily consumer-oriented, with 85% to 90% of revenues derived from consumer-related activities [2] Revenue Breakdown - 50% of QIAGEN's revenues are generated from clinical settings and lab organizations, while the other 50% comes from life sciences, including pharmaceutical and applied testing customers [2]

Summary of Qiagen Conference Call Company Overview - **Company**: Qiagen - **Industry**: MedTech, specifically focusing on diagnostics and sample preparation Key Points and Arguments Financial Performance - Qiagen reported a **6% overall growth rate** in the second quarter, indicating strong business performance despite market volatility in the U.S. academic sector and China [2][3] - **Revenue Distribution**: 50% of revenues come from clinical settings and lab organizations, while the other 50% is from life sciences, including pharma and applied testing [3] - The U.S. academic funded business, particularly from NIH, contributes about **4%** of total revenues [3] - The company has achieved a **300 basis points margin improvement** over the last two years, with an adjusted EBIT margin expected to be between **29% and 30%** this year, one of the highest in the industry [5][54] Product Highlights - **QuantiFERON-TB**: The leading product with over **20 quarters of double-digit growth**. The conversion from the traditional skin test, which still accounts for **60% to 65%** of tests, presents a significant growth opportunity [4][34] - **QIAstat-Dx**: A product for syndromic testing that saw a **30% growth rate** last quarter, aided by recent FDA approvals [5] - Upcoming product launches include the **Qiagen Symphony** replacement, **Qiagen Sprint**, and **Qiagen Mini**, aimed at expanding market presence and addressing specific customer needs [29][30] Market Dynamics - The respiratory testing market remains dominant, accounting for **70%** of the market, but there is potential for growth in multiplex and gastrointestinal testing [14][16] - Qiagen has established partnerships with pharma companies like **AstraZeneca** and **Eli Lilly** for companion diagnostics, which are expected to drive future growth [17][25] Competitive Landscape - Qiagen positions itself as a strong competitor in the symptomatic testing market, leveraging the performance and ease of use of its instruments compared to older, cumbersome systems used by competitors [9][12] - The company is focused on converting customers from traditional PCR to **digital PCR**, which offers enhanced capabilities and precision [41][42] Challenges and Opportunities - The sample preparation segment has faced challenges but is expected to improve with new product launches and a focus on automation [28] - Tariffs are projected to impact margins by **90 basis points** this year and next, but mitigation strategies are in place to minimize the absolute dollar impact on EPS [54][55] Capital Allocation and M&A Strategy - Qiagen has initiated a regular dividend and a synthetic share buyback to return value to shareholders while managing tax implications [58] - The company remains focused on bolt-on acquisitions rather than transformative moves, indicating a strategic approach to growth [59] Future Outlook - Qiagen aims for a **CAGR of 7%** for QuantiFERON and anticipates continued growth in companion diagnostics and digital PCR over the next decade [34][37][43] - The company is optimistic about achieving a margin target of over **31% by 2028**, with ongoing improvements expected despite current challenges [57] Additional Important Content - The company emphasizes the importance of R&D, allocating **9-10% of revenues** to this area, which is crucial for maintaining competitive advantage [56] - The transition to SaaS in genomics is ongoing, with expectations for a return to high single-digit growth as the transition completes [44]